Edison Inks Potential $4.3B R&D Deal With Japan Pharma Co.

Law360, New York (January 31, 2014, 8:17 PM EST) -- California-based Edison Pharmaceuticals Inc. said Friday that it has entered into a strategic alliance with Japan’s Dainippon Sumitomo Pharma Co. Ltd. potentially worth up to $4.3 billion to develop drugs targeting cellular energy metabolism.

Under the terms of the agreement, DSP will gain select development and commercialization rights in Japan and North America to jointly discovered drugs in exchange for $10 million upfront and $40 million in research and development support, Edison said in a statement.

“Our partnership with DSP codifies a common vision for developing...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.